Leo Thomas

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 603 citations

Medicine, Pharmacokinetics, Pharmacology +17

8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

Matthias Eckhardt, Elke Langkopf, Michael Mark et al. · Journal of Medicinal Chemistry · 2007 · 284 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

Leo Thomas, Matthias Eckhardt, Elke Langkopf et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 280 citations

Medicine, Medicinal Chemistry, Pharmacology +8

Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group.

John Yarnell, Chelsea Elwood, Mr Sweetnam et al. · Journal of Epidemiology & Community Health · 1984 · 158 citations · Full text

Medicine, Cardiology, Internal Medicine +15

An RNA-Seq atlas of gene expression in mouse and rat normal tissues

Julia F. Söllner, Germán Leparc, Tobias Hildebrandt et al. · Scientific Data · 2017 · 153 citations · Full text

Life Sciences, Bioinformatics, Molecular Biology +17